原文出处:MEI Pharma Announces Fast Track Designation Granted by U.S. FDA for ME-401 For the Treatment of Adult Patients with Relapsed or Refractory Follicular Lymphoma

原标题:B细胞肿瘤靶向新药!PI3Kδ抑制剂ME-401获美国FDA快速通道资格,治疗3类肿瘤总缓解率75-100%
本文来源自生物谷,更多资讯请下载生物谷APP(
http://www.bioon.com/m/)




























